Glucagon-like peptide-1

Dulaglutide ( Trulicity ) significantly improves A1C ( average blood sugar concentration over two to three months ) when added...


Findings from two phase 3a clinical trials for Semaglutide, an investigational glucagon-like peptide-1 ( GLP-1 ) analogue, were presented at...


Several studies have shown that Exenatide protects against ischemia-reperfusion injury and improves cardiac function in patients with acute ST-segment elevation...


The results from SUSTAIN-1, the first phase 3a trial for Semaglutide, a new GLP-1 analogue administered once-weekly were presented. The...


Since protein ingestion is known to stimulate the secretion of glucagon-like peptide-1 ( GLP-1 ), researchers have hypothesised that enhancing...


A follow-up study of patients with Parkinson’s disease ( PD ) who participated in an earlier proof of concept clinical...


The incretin hormone, glucagon-like peptide-1 ( GLP-1 ), promotes myocardial glucose uptake and may improve myocardial tolerance to ischemia. Endogenous...


Combination treatment with a glucagon-like peptide-1 ( GLP-1 ) agonist and basal Insulin has been proposed as a treatment strategy...


A systematic review and meta-analysis has investigated the risk of pancreatitis associated with the use of incretin-based treatments in patients...


When patients with type 2 diabetes mellitus start their first injectable therapy, clinicians can choose between glucagon-like peptide-1 ( GLP-1...


The FDA ( Food and Drug Administration ) has approved Saxenda ( Liraglutide [ rDNA origin ] injection ) as...


The FDA ( Food and Drug Administration ) has approved the New Drug Application ( NDA ) for Saxenda (...


The efficacy and safety of Lixisenatide ( Lyxumia ), a once-daily prandial glucagon-like peptide-1 ( GLP-1 ) receptor agonist, in...


Glucagon-like peptide-1 receptor agonists Exenatide ( Byetta ) and Liraglutide ( Victoza ) have been shown to improve glycaemic control...


The EMA ( European Medicines Agency ) is investigating findings by a group of independent academic researchers that suggest an...


The Committee for Medicinal Products for Human Use ( CHMP ) has finalised a review of GLP-1-based diabetes therapies. The...


Sanofi-Aventis has announced that Lixisenatide ( Lyxumia ) once-daily achieved primary efficacy endpoint and fewer hypoglycemias versus Exenatide ( Byetta...


Results from a study indicate that Exenatide injection ( Byetta ) improves blood glucose levels as effectively as Insulin Glargine...


The study was designed to assess the safety, tolerability and pharmacokinetics of Exenatide ( Byetta ) LAR (long-acting release )...


FDA ( Food and Drug Administration ) has approved Exenatide ( Byetta ), also known as synthetic exendin-4, injection as...